exposure to – Page 4 – Communicable Diseases Research

Virucidal Properties of Photocatalytic Coating on Glass against a Model Human Coronavirus

모델 인간 코로나바이러스에 대한 유리의 광촉매 코팅의 바이러스 살균 특성

Article

Published on 2022-06-292022-09-11
Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 치료제,

Mediators of Obesity Do Not Influence SARS-CoV-2 Infection or Activation of Primary Human Lung Microvascular Endothelial Cells In Vitro

비만 매개체는 SARS-CoV-2 감염 또는 시험관 내 1차 인간 폐 미세혈관 내피 세포 활성화에 영향을 미치지 않습니다

Article

Published on 2022-06-282022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 치료기술,

[키워드] activated Activation addition Adhesion Molecule adipokines adipose Adipose tissue Alter Cell cells clinical clinical observations COVID-19 Critically ill driving dysfunction E-selectin endothelial endothelial activation Endothelial cell endothelial cells Endothelial dysfunction evidenced exacerbate excess exposure to expression fat Human human lung ICAM-1 IL-6 Incubation individuals induce Infection Inflammation Inflammatory Inflammatory cytokine Inflammatory response Inflammatory responses influence initiated lack Leptin lung Lungs mechanism mediator mounted obese obese COVID-19 patients obesity observation other organs outcome phenotype plasma pro-inflammatory produced virus required response SARS-CoV-2 SARS-CoV-2 entry receptor SARS-COV-2 infection selectin severe disease shown susceptibility susceptibility to infection susceptible systemic level tested tissue VCAM-1 Viral protein Viral proteins virus visceral with COVID-19
[DOI] 10.3389/fimmu.2022.879033 PMC 바로가기 [Article Type] Article

Circulatory Exosomes from COVID-19 Patients Trigger NLRP3 Inflammasome in Endothelial Cells

COVID-19 환자의 순환 엑소좀은 내피 세포에서 NLRP3 인플라마좀을 유발합니다

Article

Published on 2022-06-282022-09-11
Journal: mBio [Category] COVID19(2023년), MERS, SARS, 유전자 메커니즘, 진단,

[키워드] Activation of caspase-1 acute respiratory syndrome acute respiratory syndrome coronavirus augmentation blood flow cargo caspase caspase-1 Cell Circulatory Coagulation Coagulopathy combating Control coronavirus coronavirus 2 COVID-19 Culture culture medium Cytokine storm demonstrated drug endothelial Endothelial cell endothelial cells ENhance examined Exosome Exosomes exposure to extracellular vesicle Extracellular vesicles Health health problem healthy donors help highlight IL-1β Immunopathogenesis induce Infection Inflammasome Inflammation Inflammatory response inhibit interleukin interleukin-1β investigator liver mechanism medium Mild Mild disease molecular molecular mechanism mRNA expression Multiple organ damage NLRP3 NLRP3 inflammasome opens organ organ damage Pathogenesis Patient plasma predicted Prevent respiratory resting resulting SARS-CoV-2 SARS-COV-2 infection secretion Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe COVID-19 patient severe COVID-19 patients significantly the vaccine Therapies Trigger Vaccine Venous Thromboembolism with mild disease
[DOI] 10.1128/mbio.00951-22 PMC 바로가기 [Article Type] Article

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern

높은 수준의 바이러스 특이적 항체가 있는 회복기 혈장은 우려되는 SARS-CoV-2 변이체를 효과적으로 중화합니다

Article

Published on 2022-06-282022-09-11
Journal: Blood advances [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody CCP convalescent plasma coronavirus correlated COVID-19 COVID-19 convalescent plasma Donor donors drug Drug administration effective effective drugs Efficacy Euroimmun Evolution examined exposure to food Food and Drug Administration high-titer CCP Hospitalization Immunoglobulin Immunoglobulin G Immunosuppressed limit Limited monoclonal antibody monoclonal antibody therapies neutralization neutralize neutralized plasma polyclonal reduce respiratory SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus Therapies variant variants virus Virus neutralization
[DOI] 10.1182/bloodadvances.2022007410 PMC 바로가기 [Article Type] Article

Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial

호흡기 감염 감소를 위한 아스토드리머 나트륨 항바이러스 비강 스프레이는 무작위 대조 시험에서 안전하고 내약성이 우수합니다.

Randomized Controlled Trial

Published on 2022-06-172022-09-11
Journal: Scientific Reports [Category] COVID19(2023년), SARS, 임상, 치료기술, 치료제,

[키워드] absorbed Absorption Administered administration adverse event All participants Antiviral applied clinical clinical investigation clinical trial clinically Cohort Community community acquired dendrimer double-blinded Effects examination finding examination findings exploratory exposure to followed by four times daily Frequency healthy volunteer help in vitro Infection initial intensity Intensive Mild nasal Nasal cavity nasal mucosa Nasal spray New nostril occurred other respiratory virus Other respiratory viruses participant Placebo placebo-controlled primary endpoint product Randomized Randomized controlled trial receiving reduce reducing Registered registry respiratory infection respiratory virus Respiratory virus infections respiratory viruses Safe safety population SARS-CoV-2 serious AEs severity shown sodium spray Spread systemically TEAE TEAEs Tolerability Treatment Trial registration utility vaginal mucosa Viral load virucidal Withdrawal
[DOI] 10.1038/s41598-022-14601-3 PMC 바로가기 [Article Type] Randomized Controlled Trial

Rapid Emergence and Spread of Severe Acute Respiratory Syndrome Coronavirus 2 Gamma (P.1) Variant in Haiti

아이티에서 중증급성호흡기증후군 코로나바이러스 2 감마(P.1) 변이의 급속한 출현 및 확산

Article

Published on 2022-06-102022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종,

Seroprevalence of Anti-S1-RBD Antibodies in Pre-pandemic and Pandemic Subjects From Hail Region, KSA

우박 지역, KSA의 전염병 전 및 전염병 대상체에서 항-S1-RBD 항체의 혈청유병률

Article

Published on 2022-06-092022-09-11
Journal: Frontiers in Public Health [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] age antibodies antibody level antibody levels Antigen asymptomatic individual Asymptomatic individuals Care clinical and demographic factors clinically collected complications Containment COVID-19 Demographic factors develop Efficacy effort ELISA exhibited exposure to female females group Hail house humoral immune responses identification immune responses in-house ELISA Infection male management neutralizing antibody new SARS-CoV-2 other coronavirus other coronaviruses pandemic positive Protein RBD antigen reduced Region required Research S-RBD S1-RBD Sample SARS-CoV-2 Screen Seroprevalence serum serum antibodies serum antibody serum IgG antibodies serum IgG antibody significantly significantly higher subject Surveillance the SARS-CoV-2 Vaccine variant variants
[DOI] 10.3389/fpubh.2022.874741 PMC 바로가기 [Article Type] Article

Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19

Covid-19 예방을 위한 근육주사 AZD7442(Tixagevimab-Cilgavimab)

Clinical Trial

Published on 2022-06-092022-09-11
Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 비임상, 신약개발, 임상, 진단, 치료제,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration adverse event adverse events age animal models assigned AstraZeneca breath cilgavimab Combination composed conducted coronavirus coronavirus disease Coronavirus disease 2019 Critical death dose Efficacy efficacy end point end point enrolled exposure to Follow-up Human incidence increased risk intramuscular injections median Mild moderate Neutralizing antibodies neutralizing antibody occurred participant pharmacokinetic data phase 3 trial Placebo placebo group prevention primary analysis Prophylactic randomization Randomized Randomly receive Relative risk reported respiratory response to vaccination risk reduction saline placebo SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severity shown single dose symptomatic COVID-19 the placebo group therapeutic effect Tixagevimab
[DOI] 10.1056/NEJMoa2116620 PMC 바로가기 [Article Type] Clinical Trial

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study

브라질에서 2회 용량 1차 프로토콜 및 BNT162b2 이종 부스터(Immunita-001)에서 비활성화된 바이러스(CoronaVac) 백신의 면역원성, 효과 및 안전성: 1년 기간의 후속 조치 4상 연구

Clinical Trial

Published on 2022-06-092022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-spike anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody antibody antibody levels Antibody titer Antibody titers approach association BNT162b2 booster booster dose Brazil Cellular immune response chemokines CoronaVac coronavirus COVID-19 COVID-19 pandemic Critical Cytokines Delta delta variant dose Effectiveness exposure to followed by growth factor Growth factors Heterologous heterologous booster highest IgG immune Immune profile immune response immunogenicity implication individual individuals Interaction maintenance male median mediators Neutralising Antibodies neutralising antibody no increase omicron Omicron variant pandemic Period phase 4 presenting protocol reduction remained respiratory restored robust Safe Safety SARS-CoV-2 Seropositivity severe acute respiratory syndrome Coronavirus significantly Spread timepoint titer titers vaccination Vaccine variant virus Year
[DOI] 10.3389/fimmu.2022.918896 PMC 바로가기 [Article Type] Clinical Trial

Benzo[ a]pyrene-Environmental Occurrence, Human Exposure, and Mechanisms of Toxicity

벤조[a]피렌-환경 발생, 인체 노출 및 독성 메커니즘

Review

Published on 2022-06-062022-09-11
Journal: International Journal of Molecular Sciences [Category] 유전자 메커니즘,